LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Search
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Speak Up – Compliance Hotline
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Mental Health
Human Pharma Clinical Pipeline Mental Health therapeutic area
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Sant Cugat del Vallès
The site in Sant Cugat del Vallès focuses on pharmaceutical production and is one of the production sites of the RESPIMAT®.
NeO - smart and sustainable vaccines
The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.
Purevax range now available in 0.5 ml presentation
Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
The Angels Initiative
The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
Transboundary animal diseases (TADs)
Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us
Oncology
Human Pharma Clinical Pipeline Oncology therapeutic area
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment